Loading...
Congenital-infantile fibrosarcoma of the foot: avoidance of amputation
Nason, GJ Baker, JF Seoighe, D Irvine, AD Mc Dermott, M Orr, D Capra, M Kelly, PM
Nason, GJ
Baker, JF
Seoighe, D
Irvine, AD
Mc Dermott, M
Orr, D
Capra, M
Kelly, PM
Advisors
Editors
Other Contributors
Departments
Date
2014-05
Date Submitted
Keywords
NEONATE
CANCER
CHEMOTHERAPY
CANCER
CHEMOTHERAPY
Other Subjects
AMPUTATION
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Article7580.pdf
Adobe PDF, 10.71 KB
Alternative Titles
Publisher
Abstract
Congenital-infantile fibrosarcoma is a rare entity with a five year survival rate of over 90%. Surgery is still the most common treatment modality with amputation often necessary. There have been reports supporting the use of neoadjuvant chemotherapy to debulk the tumour in an effort to facilitate limb sparing surgery. We report a case of a newborn who presented with a life threatening haemorrhage from a fibrosarcoma of the foot, successfully treated with Vincristine, Actinomycin and Cyclophosphamide (VAC) chemotherapy alone.
Language
en